BeyondSpring Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de BeyondSpring.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.8%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

BeyondSpring: Poor Trial Conduct And Lack Of Transparency Create Substantial Downside Risk

Sep 07

BeyondSpring's Plinabulin: Upcoming PDUFA And Positioning In The CIN Space

Aug 01

BeyondSpring EPS misses by $0.04

Jun 16

BeyondSpring reports positive plinabulin combo data for prevention of chemotherapy-induced neutropenia

Jun 07

FDA grants accelerated review to BeyondSpring's plinabulin combo application; shares up 8%

Jun 01

BeyondSpring EPS misses by $0.17

Apr 30

How Much Of BeyondSpring Inc. (NASDAQ:BYSI) Do Insiders Own?

Dec 22

BeyondSpring: Would Be A Great Buy Except For The Perennial Need For Cash And Ensuing Dilution

Dec 15

BeyondSpring slides 9% on public offering pricing at $10.0/share

Nov 19

BeyondSpring under pressure on shares offering

Nov 17

BeyondSpring's plinabulin combo meets primary endpoint in neutropenia trial

Nov 16

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como BeyondSpring no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:BYSI - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2023	2	-21	-17	-16	N/A
9/30/2023	2	-24	N/A	N/A	N/A
6/30/2023	2	-28	N/A	N/A	N/A
3/31/2023	1	-30	N/A	N/A	N/A
12/31/2022	1	-33	-28	-28	N/A
9/30/2022	1	-35	N/A	N/A	N/A
6/30/2022	1	-46	N/A	N/A	N/A
3/31/2022	1	-56	N/A	N/A	N/A
12/31/2021	1	-64	-50	-47	N/A
9/30/2021	1	-72	-37	-37	N/A
6/30/2021	1	-68	-52	-52	N/A
3/31/2021	1	-62	-52	-52	N/A
12/31/2020	0	-61	-44	-44	N/A
9/30/2020	N/A	-57	-49	-49	N/A
6/30/2020	N/A	-52	-60	-60	N/A
3/31/2020	N/A	-47	-54	-54	N/A
12/31/2019	N/A	-38	-48	-48	N/A
9/30/2019	N/A	-38	-44	-44	N/A
6/30/2019	N/A	-44	-31	-31	N/A
3/31/2019	N/A	-49	-36	-36	N/A
12/31/2018	N/A	-55	-40	-40	N/A
9/30/2018	N/A	-56	-42	-42	N/A
6/30/2018	N/A	-57	-40	-40	N/A
3/31/2018	N/A	-58	-33	-32	N/A
12/31/2017	N/A	-92	-29	-29	N/A
9/30/2017	N/A	-80	N/A	-24	N/A
6/30/2017	N/A	-67	N/A	-19	N/A
3/31/2017	N/A	-58	N/A	-17	N/A
12/31/2016	N/A	-12	N/A	-14	N/A
9/30/2016	N/A	-10	N/A	-11	N/A
6/30/2016	N/A	-9	N/A	-9	N/A
3/31/2016	N/A	-8	N/A	-7	N/A
12/31/2015	N/A	-8	N/A	-7	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de BYSI es superior a la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de BYSI crezcan más rápidamente que el mercado US

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de BYSI crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de BYSI crezcan más rápidamente que el mercado de US.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de BYSI crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de BYSI se prevé que sea elevada dentro de 3 años.

BeyondSpring Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased to US$2.30

Price target decreased to US$6.10

Consensus forecasts updated

Price target increased to US$13.67

Consensus revenue estimates fall by 90%

Consensus forecasts updated

Recent updates

New minor risk - Market cap size

BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Rule

First half 2023 earnings released: US$0.33 loss per share (vs US$0.47 loss in 1H 2022)

New major risk - Revenue and earnings growth

BeyondSpring Inc. Announces New Data That Translates Preclinical Proof-Of-Concept to Clinical Evidence of Plinabulin’s Immunomodulating Activity

New minor risk - Financial data availability

BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Requirement

New major risk - Share price stability

BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

BeyondSpring Inc. Announces Retirement of Yanbin Xie as Board of Director

Here's Why We're Watching BeyondSpring's (NASDAQ:BYSI) Cash Burn Situation

BeyondSpring Inc. Announces New Data from Phase 1 Investigator Initiated Study Plinabulin’s Ability to Reduce Infectious Neutropenic Fever for Multiple Myeloma Patients Undergoing AHCT

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

BeyondSpring Receives Notifications from Nasdaq Regarding Compliance With Listing Rules

BeyondSpring Inc. Announces the Resignation of Christine Ying Zhao from the Board of Directors, Effective January 1, 2023

BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

Price target decreased to US$2.30

BeyondSpring Inc. Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Monocyte Progenitor Stem Cells for the Prevention of Chemotherapy-Induced Neutropenia at the ESMO Congress 2022

BeyondSpring Inc. Announces Board Appointments

BeyondSpring Inc.(NasdaqCM:BYSI) dropped from Russell 2000 Dynamic Index

BeyondSpring Inc. Announces Executive Resignations, with Effect from June 9, 2022

BeyondSpring Inc. Announces Resignation of Gordon L. Schooley as Chief Regulatory Officer

Price target decreased to US$6.10

Elizabeth Czerepak Resigns as Executive Vice President of BeyondSpring Inc

Consensus forecasts updated

Price target increased to US$13.67

BeyondSpring Inc. to Report Q4, 2021 Results on Apr 14, 2022

BeyondSpring, Beyond Salvage

BeyondSpring Pharmaceuticals Announces Organizational Streamlining

Consensus revenue estimates fall by 90%

BeyondSpring Pharmaceuticals Announces New Clinical Data Confirming Plinabulin’s Fast Onset Mechanism of Action in Prevention of Chemotherapy-Induced Neutropenia at 63rd ASH Annual Meeting and Exposition

Consensus forecasts updated

BeyondSpring Pharmaceuticals Receives Complete Response Letter from the FDA for Plinabulin New Drug Application for Prevention of Chemotherapy-Induced Neutropenia (CIN)

No longer forecast to breakeven

Circling Back On BeyondSpring

Price target decreased to US$58.60

Upcoming News For BeyondSpring's Plinabulin Tees Up Big Potential Returns

BeyondSpring: Poor Trial Conduct And Lack Of Transparency Create Substantial Downside Risk

Price target increased to US$67.25

BeyondSpring's Plinabulin: Upcoming PDUFA And Positioning In The CIN Space

Consensus forecasts updated

BeyondSpring Inc.(NasdaqCM:BYSI) dropped from Russell Microcap Value Index

Consensus forecasts updated

BeyondSpring EPS misses by $0.04

BeyondSpring Announces Final Positive Data from the PROTECTIVE-1 Phase 3 CIN Program of Plinabulin as a Single Agent Compared to Pegfilgrastim at the American Society of Clinical Oncology (ASCO) Annual Meeting

BeyondSpring reports positive plinabulin combo data for prevention of chemotherapy-induced neutropenia

BeyondSpring Announces First Patient Dosed in a Triple Combination Study with Plinabulin, PD-1/PD-L1 Inhibitor and Radiotherapy for the Reversal of Resistance to PD-1/PD-L1 Inhibitors in Patients with Advanced Solid Tumors

BeyondSpring Inc. Announces U.S. FDA Acceptance and Priority Review of New Drug Application for Plinabulin and G-CSF Combination for the Prevention of Chemotherapy-Induced Neutropenia

FDA grants accelerated review to BeyondSpring's plinabulin combo application; shares up 8%

BeyondSpring EPS misses by $0.17

BeyondSpring Announces Five Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting

Chief Scientific Officer has left the company

BeyondSpring Inc. Announces Management Changes

Price target lowered to US$36.00

How Much Of BeyondSpring Inc. (NASDAQ:BYSI) Do Insiders Own?

BeyondSpring Announces the Appointment of Dr. Jeffrey Vacirca to its Board of Directors

BeyondSpring: Would Be A Great Buy Except For The Perennial Need For Cash And Ensuing Dilution

BeyondSpring Announces New Positive PROTECTIVE-2 Phase 3 Registrational Trial Results at the 2020 San Antonio Breast Cancer Symposium

BeyondSpring Inc. has completed a Follow-on Equity Offering in the amount of $75 million.

BeyondSpring slides 9% on public offering pricing at $10.0/share

BeyondSpring Announces Positive Topline Results from Its PROTECTIVE-2 Phase 3 Registrational Trial of Plinabulin in Combination with Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia

BeyondSpring under pressure on shares offering

BeyondSpring's plinabulin combo meets primary endpoint in neutropenia trial

New 90-day high: US$16.02

BeyondSpring Forms Partnership Advisory Committee

New 90-day high: US$15.36

BeyondSpring Inc. Announces JAMA Oncology Highlights Plinabulin's Efficacy in Preventing Chemotherapy-Induced Neutropenia as a Monotherapy

BeyondSpring Inc. Announces New Clinical Data on Late-Stage Asset, Plinabulin

BeyondSpring Inc. Appoints Elizabeth Czerepak as Chief Financial Officer